Navigation Links
Poliovirus vaccine trial shows early promise for recurrent glioblastoma
Date:5/21/2013

DURHAM, N.C. An attack on glioblastoma brain tumor cells that uses a modified poliovirus is showing encouraging results in an early study to establish the proper dose level, researchers at Duke Cancer Institute report.

The treatment, developed at Duke and tested in an ongoing phase 1 study, capitalizes on the discovery that cancer cells have an abundance of receptors that work like magnets drawing the poliovirus, which then infects and kills the cells.

The investigational therapy, known as PVSRIPO, uses an engineered form of the virus that is lethal to cancer cells, while harmless to normal cells. Infused directly into the patient's tumor, the virus-based therapy also triggers the body's immune fighters to launch an attack against the infected tumor cells.

Preliminary data, presented at the upcoming 2013 Annual Meeting of the American Society of Clinical Oncology in Chicago (ASCO abstract #2094), previews the results of seven patients enrolled in the study whose tumors reoccurred despite traditional treatments for glioblastoma multiforme, the most common and aggressive brain tumor.

Of the patients enrolled in the study, three have responded well to the drug. One patient remains disease-free 12 months after treatment, another 11 months post-treatment and the third is disease-free after five months. With traditional treatment, about half of glioblastoma patients see recurrent tumor growth within eight weeks.

Two patients in the study did not fair as well; one had recurrent tumor growth after two months, and another's condition declined after four months. The remaining two patients have been treated in the last three and two months, respectively, and currently remain disease free.

"These early results are intriguing," said Annick Desjardins, M.D., FRCPC, principal investigator and associate professor of medicine at Duke University School of Medicine. "Current therapies for glioblastoma are limited because they cannot cross the blood-brain barrier and often do not specifically attack the tumor. This treatment appears to overcome those problems. We are eager to see additional results as we move forward with our study."


'/>"/>

Contact: Sarah Avery
sarah.avery@duke.edu
919-660-1306
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. Study: Older Whooping Cough Vaccine More Effective
2. Whole-cell vaccine was more effective than acellular vaccine during CA pertussis outbreak
3. Cocaine vaccine passes key testing hurdle
4. Immune Cell Discovery May One Day Lead to Herpes Vaccine: Study
5. TransactRx Releases Part 1 of Series – Buying Vaccines from Group Purchasing Organizations
6. TB, HIV and malaria vaccine research gets major boost
7. Flu Vaccine Safe for Kids With Crohns, Colitis: Study
8. Flu vaccine safe for children with IBD: Study
9. Focus on STD, not cancer prevention, to promote HPV vaccine use
10. Study compares effectiveness of 2 vs. 3 doses of HPV vaccine for girls and young women
11. Nottingham-China research collaboration holds hope for bovine and human TB vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... 2016 , ... The Valentine’s Season is famous for gift giving with flowers, chocolates and other ... loved. This year, for more than 5.6 million Americans suffering with Alzheimer’s, those store ... to remind them of the lives they’ve led and the people they’ve touched. ...
(Date:2/8/2016)... ... 08, 2016 , ... Tingley Rubber Corporation , a ... its range of unique and advantaged protective solutions to a growing and ... bilingual customer service and marketing support. A new distribution center in Brampton, Ontario ...
(Date:2/8/2016)... ... February 08, 2016 , ... Delta Dental of California ... combat pancreatic cancer. , Gary D. Radine, who recently retired as president and CEO ... Cancer Society’s 2015 CEO of the Year , helped lead the effort to ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... wide variety of organizations. DocuSyst provides a cloud hosted environment for FileHold ... installations include integration with various 3rd party applications using the FileHold web services ...
(Date:2/8/2016)... , ... February 08, 2016 , ... TopConsumerReviews.com recently awarded ... Mole removal products. , Moles are derived from a cluster of melanin when exposed ... the wrong places and create a lifetime of embarrassment. Historically, mole removal ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... 2016  Syneron Medical Ltd. (NASDAQ: ELOS ... today that William Griffing , Chief Executive ... to participate in the Leerink Partners 5 th ... 2016 in New York City ... meet with the Mr. Griffing and will include ...
(Date:2/5/2016)... Feb. 5, 2016  As people age, it is ... of recommended screenings and tests that are linked with ... However, for the majority of aging individuals, hearing health ... For the 37.5 million American adults who report some ... to make hearing health a 2016 healthy aging priority.[1] ...
(Date:2/5/2016)...  Aralez Pharmaceuticals Inc. ("Aralez") today announced the completion ... Pharmaceuticals Canada Inc. ("Tribute") following approval of the transaction ... combined company will operate under Aralez Pharmaceuticals Inc. ("Aralez"), ... Canada , Ireland ... the terms of the Agreement and Plan of Merger ...
Breaking Medicine Technology: